natgillin/translations-raw huggingface dataset:
phenyl, pyridinyl, pyrimidinyl, pyrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, isoxazolyl, all of which are optionally substituted with 1-3 substituents independently selected from the group consisting of C1-C6 alkyl optionally substituted with hydroxy, dimethylamino, pyrrolidinyl, piperidinyl, or morpholinyl, C2-C6 alkenyl optionally substituted with dimethylaminocarbonyl, C1-C6 alkoxy, trifluoromethyl, difluoromethoxy, trifluoromethoxy, dimethylaminoethoxy, phenoxy, tolyl, halo, methylsulfonyl, dimethylamino, diethylamino, cyano, C3-C6 cycloalkyl optionally substituted with hydroxy, methoxy, methoxyethoxy, or methyl, 3,4-dimethylisoxazol-5-yl-aminosulfonyl, tetrahydropyranyl, tetrahydropyranylaminocarbonyl, C2-C6 alkylcarbonyl, morpholinylcarbonyl, and piperazinylcarbonyl; or pharmaceutically acceptable salts thereof. 
fenil, piridinil, pirimidinil, pirazolil, tiazolil, izotiazolil, tiadiazolil, izoksazolil, od kojih su svi izborno supstituirani s 1-3 supstituenta, koje se neovisno bira iz skupine koju čine C1-C6 alkil, izborno supstituiran s hidroksi, dimetilamino, pirolidinilom, piperidinilom ili morfolinilom, C2-C6 alkenil, izborno supstituiran s dimetilaminokarbonilom, C1-C6 alkoksi, trifluormetilom, difluormetoksi, trifluormetoksi, dimetilaminoetoksi, fenoksi, tolilom, halogenom, metilsulfonilom, dimetilamino, dietilamino, cijano, C3-C6 cikloalkil, izborno supstituiran s hidroksi, metoksi, metoksietoksi ili metilom, 3,4-dimetilizoksazol-5-ilaminosulfonil, tetrahidropiranil, tetrahidropiranilaminokarbonil, C2-C6 alkilkarbonil, morfolinilkarbonil i piperazinilkarbonil; ili njegove farmaceutski prihvatljive soli.
Thus, the disclosure provides an antibody that binds to an epitope recognised by an antibody having the variable heavy chain sequence recited in SEQ ID NO: 97, and the variable light chain sequence recited in SEQ ID NO: 111. 
Humano monoklonsko terapeutsko protutijelo anti-ActRIIB, prema zahtjevu 6, naznačeno time, da obuhvaća varijabilno područje slabog lanca od sekvence SEQ ID NO: 93, i varijabilno područje jakog lanca od sekvence SEQ ID NO: 107.
The obesity treatment device according to any one of the preceding claims, wherein the obesity treatment device comprises at least two expandable stretching devices (410b) adapted to stretch at least two different portions of the stomach wall. 
Uređaj u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedeni uređaj ima najmanje dva upravljiva uređaja za rastezanje (410b), prilagođena za rastezanje najmanje dva različita dijela stijenke želuca, gdje je uređaj prilagođen za postoperativno i nemvazivno upravljanje.
Preferred herbicidal mixtures or combinations according to the invention are the following 
Poželjne herbicidne smjese ili kombinacije prema izumu su slijedeće
After completion of the addition, the mixture was left to warm to room temperature, then gradually heated to ebullition to obtain a clear solution (approx. 2 hours), which was cooled, the residue was filtered and concentrated under vacuum. 
Nakon završetka dodavanja, smjesa je ostavljena da se ugrije do sobne temperature te je postupno zagrijana do vrenja da se dobije bistra otopina (približno 2 sata) koja je ohlađena, ostatak je filtriran i uparen pod vakuumom.
an HVR-L3 comprising the amino acid sequence of SEQ ID NO:13. 
HVR-L3 koji sadrži aminokiselinsku sekvencu od SEQ ID NO:13; pri čemu po želji slabi lanac obuhvaća:
The procedure for obtaining the vaccine composition according to Claim 14, wherein the conjugated protein is purified by a ultrafiltration/diafiltration method using a membrane having a pore size of 100 kDa. The vaccine composition comprising as active principle the conjugated protein hrEGFrP64K, wherein said vaccine composition is purified by the procedure of Claim 15. 
Sastav cjepiva prema zahtjevu 1, koji kao aktivni sastavni element sadrži konjugirani protein hrEGF-rP64K, naznačen time, da se spomenuti sastav cjepiva purificira postupkom prema bilo kojem zahtjevu od 9 do 13.
The compound of claim 5, wherein Ar is 5 or 6 membered heteroaryl selected from indolyl, pyrrolyl, imidazolyl, pyrazolyl, benzimidazolyl, thienyl, furanyl, pyridinyl and pyrimidinyl, each optionally substituted. 
Spoj zahtjeva 5, naznačen time, da je Ar heteroaril s 5 ili 6 članova izabran od indolil, pirolil, imidazolil, pirazolil, benzimidazolil, tienil, furanil, piridinil i pirimidinila, svaki je opcijski supstituiran.
A method for treating nonalcoholic fatty liver disease (NAFLD) or hepatic insulin resistance in humans comprising the step of administering to an animal the human in need of such treatment a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 
Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 14, ili pripravak u skladu s bilo kojim od patentnih zahtjeva 15 do 17, naznačeni time što su namijenjeni upotrebi u liječenju nealkoholne bolesti masne jetre (NAFLD) ili jetrene otpornosti na inzulin.
Mould system and method for operating said system 
SUSTAV KALUPA I UPORABA SUSTAVA KALUPA
In a first aspect the invention relates to the use of hydrophobic charge-induction chromatography for purification of IL-18BP. 
U svom prvom aspektu izum se odnosi na uporabu kromatografije s hidrofobnom indukcijom naboja za pročišćavanje IL-18BP.
The use of a compound of any one of claims 1 to 3 in free base or pharmaceutically acceptable acid addition salt form, as a pharmaceutical for the treatment or prevention of a disease or condition in which a7 nAChR activation plays a role or is implicated. 
Spoj formule I prema bilo kojem zahtjevu 1 do 10, koji je u slobodnom bazičnom obliku ili u obliku farmaceutski prihvatljive dodatne kiselinske soli, naznačen time, da se upotrebljava za liječenje ili prevenciju bolesti ili stanja u kojima igra ulogu aktiviranje a7-nACRR ili je implicirano aktiviranje a7-nAChR.
reacting a compound of formula II wherein R1 is hydrogen, fluoro or chloro; with a nitration agent to the compound of formula III wherein R1 is hydrogen, fluoro or chloro; 
reakciju spoja formule II, pri čemu R1 je vodik, fluor ili klor; sa sredstvom za nitriranje u spoj formule III
wherein p ranges from about 3 to about 5. 
gdje je p u rasponu od 1 do 10.
As the wall elements are hardly loaded, they are not deformed and this obviates the need for frames around windows which are normally intended to protect the glass from forces in the wall. 
Kako su zidni elementi pod gotovo nikakvim opterećenjem, ne deformiraju se i time nestaje potreba za okvirima oko prozora koji su inače namijenjeni tome da štite staklo od sila u zidu.
determining by quantitative PCR in said human feces sample the concentration of at least one 16S rDNA bacterial sequence selected from the group consisting of SEQ ID NO: 7 and SEQ ID NO: 10, wherein SEQ ID NO: 7 concentration is determined using primers with at least 90% identity with respect to SEQ ID NO: 8-9, and SEQ ID NO: 10 concentration is determined using primers with at least 90% identity with respect to SEQ ID NO: 11-12; 
2 odnosno 13; kvantificiranje razina SEQ ID NO: 4 se određuje upotrebom početnica s najmanje 90 % istovjetnosti sa SEQ ID NO: 5 odnosno 6; kvantificiranje razina SEQ ID NO: 7 se određuje upotrebom početnica s najmanje 90 % istovjetnosti sa SEQ ID NO: 8 odnosno 9; 1 kvantificiranje razina SEQ ID NO: 10 se određuje upotrebom početnica s najmanje 90 % istovjetnosti sa SEQ ID NO: 11 odnosno 12.
The reaction mixture was extracted with ethyl acetate, the two phases were separated and the organic phase was washed with brine, dried with MgSO4 and concentrated in vacuo to give (2-allylsulfanyl-benzyl)-carbamic acid tert-butyl ester in quantitative yield. 
Reakcijska smjesa se tada ekstrahira etil acetatom, dvije faze se separiraju i organska faza se pere u rasolu i suši s MgSO, te koncentrira in vacuo kako bi se dobilo (2-alilsulfanilbenzil) karbaminska kiselina tert-butil ester u kvantitativnoj količini.
In one embodiment, the composition is a pharmaceutical composition (e.g., formulation, preparation, medicament) comprising methylthioninium chloride dihydrate form B, C or D or methylthioninium chloride monohydrate form E, as described herein, and a pharmaceutically acceptable carrier, diluent, or excipient. 
Farmaceutski pripravak, naznačen time, da sadrži metiltioninium klorid monohidrat u Obliku E prema zahtjevu 1 ili zahtjevu 2, i opcionalno farmaceutski prihvatljiv nosač, ekscipijent ili razrjeđivač. 5. - Metiltioninium klorid monohidrat u Obliku E prema zahtjevu 1 ili zahtjevu 2, naznačen time, da služi za uporabu 20
a receptacle tank (220) for receiving wastewater to be treated, the receptacle tank being provided with a first outlet pipe (8') and a second outlet pipe (10'); 
(a) prijemni spremnik (220) za prijem otpadne vode koju treba preraditi, taj prijemni rezervoar ima prvu izlaznu cijev (8*) i drugu izlaznu cijev (10");
Process of claim 1, wherein said hot gas consisting of hot air and superheated steam has a temperature comprised between 150 and 190°C, preferably between 160 and 175°C. 
Postupak sukladno zahtjevu 1, pri čemu vrući plin koji se sastoji od vrućeg zraka i zagrijane pare ima temperaturu između 150 1 190%, poželjno između 160 i 175%C.
applying refractory grains into the liquid lacquer coat, drying of the liquid lacquer coat until it forms a hardened refractory coating together with the refractory grains. 
Mixa: oblikovanje tekućeg lakiranog premaza na njoj; nanošenje vatrostalnih zrnaca na tekući lakirani premaz; sušenje tekućeg lakiranog premaza dok se ne oblikuje stvrdnuta vatrostalna obloga (20) zajedno s vatrostalnim zrncima.
converting the quantization coefficient information into a two-dimensional quantization block; 
modul za inverzno skeniranje konfiguriran da konvertira informacije o koeficijentu kvantizacije u dvodimenzionalni kvantizacijski blok;
The term "isomeric purity" in the present context refers to the amount of 3,11b- cis- dihydrotetrabenazine Isomer D present relative to the total amount or concentration of dihydrotetrabenazine of all isomeric forms. 
Izraz "izomerna čistoća" u prikazanom kontekstu se odnosi na prisutnu količinu 3,11b-cis-dihidrotetrabenazin Izomera A relativno prema ukupnoj količini ili koncentraciji dihidrotetrabenazina u svim izomernim oblicima.
The hydroboration-oxidation-hydrolysis sequence of reactions of Process A typically provides dihydrotetrabenazine isomers in which the hydrogen atoms at the 2- and 3-positions have a trans relative orientation. 
Hidroboriranje-oksidacija-hidroliza redoslijed reakcija Postupka A obično daje izomere dihidrotetrabenazina u kojima vodikovi atomi u položajima 2- 1 3- imaju trans relativnu orijentaciju.
culturing, in suspension in a serum-free medium, mammalian cells transfected with at least one plasmid adapted for the production of a lentiviral vector, the culture being carried out in a volume of at least 5 L; 
- uzgoju, u suspenziji u mediju koji ne sadrži serum, stanica HEK293T transficiranih najmanje jednim plazmidom prilagođenim za proizvodnju lentivirusnog vektora, gdje se uzgoj provodi u volumenu od najmanje 50 1;
a bispecific antibody (Q85-G4k/J321-G4h/L334-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 11, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 5, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 30; a bispecific antibody (Q153-G4k/J232-G4h/L406-k), wherein the first polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 12, the second polypeptide is an H chain consisting of the amino acid sequence of SEQ ID NO: 21, and the third polypeptide and the fourth polypeptide are a commonly shared L chain of SEQ ID NO: 33; 
5, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 30; bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 12, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 21, a treći polipeptid 1 četvrti polipeptid su zajednički korišten L-lanac od SEQ ID NO: 33; bispecifično protutijelo, gdje prvi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO: 13, drugi polipeptid je H-lanac koji se sastoji od aminokiselinske sekvence od SEQ ID NO:
• Phase L/c4) Progressive update of the energy received from the utility grid for each node; 
. Faza 1./c4) progresivno ažuriraj energiju primljenu iz komunalne mreže za svaki čvor;
A process for the preparation of a compound of Formula (I) according to claim 1, wherein G is an alkyl, acyl, phosphoryl or sulfonyl group, which comprises treating the compound of the formula (A) 
Postupak priprave spoja formule (I) prema zahtjevu 1, pri čemu G je alkil, acil, fosforil ili sulfonil skupina, naznačen time, da obuhvaća tretiranje spoja formule (A)
The information system according to claim 1, wherein the absorber comprises one or more of the following features: a dark colour paint; and an absorbing structure. 
Informacijski sustav u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje prigušivač (10) sadrži jednu ili više sljedećih svojstava: tamnu boju; i strukturu koja upija.
The fibres 10 extend in this structure in an almost disorderly manner. FIG. 
Ova vlakna 10 se pružaju u ovoj strukturi na takav način da su potpuno bez reda.
A method according to claim 1, wherein at least one wall of the casting mould is moved during a period of time which is about 25% before the end of the steaming phase and about 25% from the beginning of the cooling phase after the steaming phase. 
Postupak prema zahtjevu 1 ili 2, naznačen time što se barem jedna stjenka kalupa za lijevanje pomiče tijekom vremenskog perioda koji je 25 % prije kraja parne faze i 25 % od početka faze hlađenja nakon parne faze.
the second binding domain is capable of binding to CD3; and wherein epitope cluster 3 of BCMA corresponds to amino acid residues 24 to 41 of the sequence as depicted in SEQ ID NO: 1002, and epitope cluster 4 of BCMA corresponds to amino acid residues 42 to 54 of the sequence as depicted in SEQ ID NO: 1002, and wherein said binding molecule is a polypeptide. 
druga vezujuća domena sposobna je za vezanje na CD3; i pri čemu epitop klastera 3 od BCMA odgovara ostatcima aminokiseline 24 do 41 od sekvence kao što je prikazano u SEQ ID NO: 1002, i pri čemu je navedena vezujuća molekula polipeptid.
A tenth example concerns the gelation of pastry creams in which the following ingredients are used: 
U desetom primjeru opisuje se geliranje kreme za kolače i torte, za što su potrebni sljedeći sastojci:
These solutions may also contain stabilizing ingredients and/or buffering ingredients and are dispensed into unit doses in the form of ampoules or vials. 
Ove otopine mogu također sadržavati stabilizatorske agense i/ili agense za puferiranje te su raspoređene u doznim jedinicama u obliku ampula ili fijala.
Next, 0.8mL of 48% HF aqueous was added slowly to the reaction solution and the reaction stirred in the ice/water bath for 20 minutes. 
Nadalje, polagano je bilo dodano 0.8 mL vodenog 48%-tnog HF u reakcijsku otopinu i reakcijska smjesa je bila miješana u kupelji led/voda kroz 20 minuta.
The specific activity of IL-18BP is calculated according to the following formula: EPMATHMARKEREP 
Specifična aktivnost IL-18BP izračunata je sukladno slijedeće formule:
Hydroxypropylmethyl cellulose, water and simethicone were mixed. 
Hidroksipropilmetil celuloza, voda i simetikon se pomiješaju.
An organic amine salt of 6-fluoro-3-hydroxy-2-pyrazinecarbonitrile, wherein the organic amine is dicyclohexylamine. 
Organska aminska sol 6-fluoro-3-hidroksi-2-pirazinkarbonitrila, naznačena time, da je organski amin dicikloheksilamin.
The sartan for use according to any one of claims 1 to 6, characterized in that the pharmaceutical composition is to be administered to a cat in a therapeutically effective amount that result in a cumulative intravenous dose of the sartan of at least about 0.025 mg/kg of body weight. 
Sartan za uporabu prema bilo kojem od zahtjeva 1 do 6, naznačen time, da se farmaceutski sastav primjenjuje na mački u terapeutski djelotvornoj količini koja dovodi do kumulativne intravenozne doze sartana od najmanje oko 0,025 mg po kilogramu tjelesne mase.
A compound or pharmaceutically acceptable salt thereof for use according to claim 5 in the treatment of type 2 diabetes. 
Spoj, ili njegova farmaceutski prihvatljiva sol, naznačen time što je namijenjen upotrebi u skladu s patentnim zahtjevom 5, u liječenju dijabetesa tip 2.
The method of claim 16, comprising an amino acid sequence at least 90% identical to the amino acid sequence of SEQ ID NO:35 residues 1-378. 
Polipeptid iz bilo kojeg od patentnih zahtjeva 1-4, koji sadrži aminokiselinsku sekvencu najmanje 95% identičnu aminokiselinskoj sekvenci u skladu sa SEK ID BR:1 ili SEK ID BR:35.
a light chain variable domain comprising an amino sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 55, and a heavy chain variable domain comprising an amino sequence that is at least 95% identical to the amino acid sequence of SEQ ID NO: 56 or SEQ ID NO: 57, wherein the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 69, 66 and 60, and the heavy chain variable domain comprises the amino acid sequences of SEQ ID NO: 61, 62 and 63; or 
) = protutijelo ili njegov fragment koji se veže na antigen sadrži varijabilni lagani lanac koji sadrži sekvencu aminokiseline od SEQ ID NO: 55, i varijabilni teški lanac koji sadrži sekvencu aminokiseline od SEQ ID NO: 56 ili SEQ ID NO: 57; k) - protutijelo ili njegov fragment koji se veže na antigen sadrži: (i) - sekvence aminokiselina RSSKSLLHSSGKTILYW (SEQ ID NO: 69), RMSNLA (SEQ ID NO:
The pharmaceutical composition for use according to one of claims 6 to 9, wherein the optional glidant is colloidal silicon dioxide. 
Farmaceutski pripravak sukladno jednom od zahtjeva 1 do 8, naznačeno time da je opcioni glidant koloidni silicij dioksid.
A compound according to claim 1 of the following formula: or a pharmaceutically acceptable salt, solvate, or amino acid conjugate thereof. 
& x. li " . u: ća % Fi ili njegova farmaceutski prihvatljiva sol, solvat ili aminokiselinski konjugat.
The 13th item relates to a floor panel according to any of the preceding items, characterized in that it comprises a press-on portion (15) effecting laterally on the lock-up body (14). 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što sadrži dio na pritisak (15) koji lateralno djeluje na tijelo za zaključavanje (14).
The present invention relates to application of a biologically active or chemical substance to relatively large volumes of target product, one example being pre-harvested or harvested crop, and in particular, to an apparatus, method, and system of applying biologically active or chemical substance in a minute ratio to the target product, whether it is moving relative to the substance, the substance is moving relative to it, or both. 
Ovaj se izum odnosi na nanošenje jedne biološki aktivne ili kemijske supstance na relativno velike količine ciljnog proizvoda, čiji su primjer nepožnjeveni ili požnjeveni usjevi, a posebno na uređaj, postupak i sustav za nanošenje biološki aktivne ili kemijske supstance u nekom minimalnom razmjeru na ciljni proizvod, bila da se on kreće u odnosu na supstancu, bilo da se supstanca kreće u odnosu na njega, bilo i jedno i drugo istovremeno.
The method of claim 16, wherein the cancer is breast cancer, thyroid cancer, colorectal cancer, endometrial cancer, fallopian tube cancer, ovarian cancer or lung cancer. 
Postupak u skladu s patentnim zahtjevom 20, naznačen time što je rak rak dojke, rak štitnjače, kolorektalni rak, rak endometrija, rak jajovoda, rak jajnika ili rak pluća.
An isolated osteogenic placental adherent cell (OPAC), wherein said cell is obtained from chorion, and is adherent to tissue culture plastic, and wherein said cell is negative for CD200 or is CD200dim and positive for CD105. 
Izolirana osteogena placentalna adherentna stanica (OPAC), naznačena time što se navedenu stanicu dobiva iz koriona, prianja na plastičnu podlogu za kulturu tkiva, što je navedena stanica negativna na CD200 ili je CD200€", te je pozitivna na CD105.
A compound of claim 1 for use as a medicament for treating pantothenate kinase-associated neurodegeneration in a subject. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je namijenjen upotrebi kao medikament za liječenje neurodegeneracije povezane s pantotenat-kinazom kod subjekta.
The siRNA according to claim 1, wherein a nucleotide is a nucleotide analog having chemically modified sugar, base, and/or phosphate. A pharmaceutical composition comprising the siRNA according to claim 1 or 2. 
siRNA u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačena time, da je nukleotid analog nukleotida koji ima kemijski sastav modificiranog šećera, baze i / ili fosfata.
In a further instance, X is 4-pyridinyl optionally substituted with one group selected from C1-C4 alkyl, cyclopropyl, cyclopropyloxy, cyclopropylmethyl, C1-C4 alkoxy, CF3, amino, alkylamino, dialkylamino, thioalkyl, halogen, alkylsulfonyl and cyano. 
Spoj prema zahtjevu 8, naznačen time da je X 4-piridinil opcionalno supstituiran jednim supstituentom izabranim iz skupine koju sačinjavaju C;-C4 alkil, ciklopropil, ciklopropiloksi, ciklopropilmetil, C,-Ca alkoksi, CF3, amino, alkilamino, dialkilamino, tioalkil, halogen, alkilsulfonil i cijano.
The optical element according to claims 7 or 8, wherein the exit surface of the optical element has a tilted upper portion which in use is to shade a relatively lower portion of the exit surface from snow and/or dust. 
Optički element u skladu sa patentnim zahtjevima 6 ili 7, gdje izlazna površina optičkog elementa ima nagnuti gornji dio koji se koristi da zasjeni relativno niži dio izlazne površine od snijega i/ili prašine.
wherein said antibody does not have binding specificity for IL-6R or gp130, preferably wherein the IL-6R is soluble IL-6R (sIL-6R), 
gdje navedeno protutijelo nema specifičnost vezanja za topljivi IL-6R (sIL-6R) ili gp130,
Such brain injury may be induced by traumatic, inflammatory, infectious, neoplastic, vascular, hypoxic or metabolic causes or by toxic reactions to exogenous chemicals, wherein the exogenous chemicals are selected from the group consisting of substances of abuse, pharmaceutical compounds, and environmental toxins. 
Farmaceutski pripravak prema zahtjevu 8, naznačen time, što je za poboljšanje motoričkih funkcija, kognitivnih funkcija i srodnih emocionalnih poremećaja, a nakon ozljede mozga induciran traumatskim, upalnim, infektivnim, neoplastičnim, vaskularnim, hipoksičkim ili metaboličkim uzrocima ili ozljeda mozga inducirana toksičnim reakcijama na egzogenim kemikalijama, pri čemu su egzogene kemikalije odabrane iz skupine koja se sastoji od zloupotrebe supstance, farmaceutskih spojeva, toksina okoliša,
is a hydrogen atom, a C1-6 alkyl group optionally substituted by one or more C1-6 alkoxy groups, a C1-6 alkanoyl group, a C1-6 alkylsulfonyl group, or a phenyl C1-6 alkyl group: 
R* je atom vodika, C; alkil skupina opcijski supstituirana s jednom ili više C;.4 alkoksi skupina, C;.4 alkanoil skupina, Ci. alkilsulfonil skupina, ili fenil C;.4 alkil skupina;
A fan assembly as claimed in claim 19, wherein the surface (42) is a Coanda surface. 
Ventilatorski sustav prema zahtjevu 19, gdje je površina (42) Coanda površina.